GMDN invests in new equipment as post-market database nears launch
This article was originally published in Clinica
The trustees of the Global Medical Device Nomenclature (GMDN) Agency have agreed to invest €350,000 ($469,000) in additional IT hardware and software for the naming system.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.